This report provides an update to the comprehensive literature search previously conducted on behalf of the Department of Health. To inform activities related to GBMA Education’s Biosimilar Education Grant, these reviews examine all international and ...
Ward, M., Staff, K., Reuter Lange, S.
core
Weiguang Xue,1 Adam Lloyd,1 Edel Falla,1 Claudia Roeder,2 Rudiger Papsch,2 Klaus Bühler3,41IQVIA, Real-World Evidence, London, UK; 2Merck KGaA, Frankfurt, Germany; 3Centre for Gynecology Endocrinology & Reproductive Medicine Kinderwunsch-Zentrum
Xue W +5 more
doaj
[Successful switch from originator to biosimilar growth hormone: patients' experiences]
OBJECTIVE: To survey patients' experiences with the switch from an originator biologic to a biosimilar growth hormone. DESIGN: Questionnaire. METHOD: We developed a questionnaire in which patients were asked about their experiences with the switch from ...
Repping-Wuts, H. +7 more
core
Comparing prescribing and spending across originator, follow-on, and interchangeable biosimilar insulin glargine: Opportunities to improve uptake of biosimilar medications. [PDF]
Abrams LM, Funk K, Farley JF.
europepmc +1 more source
The uptake of biosimilar products by British formularies
OBJECTIVES: A “biosimilar” is a biological medicine similar to a licensed biological medicine (“originator”). As of October 2014, six biosimilars are licensed and marketed in Great Britain (GB) (three biosimilar filgrastims, two biosimilar epoetins and ...
Murray Smith (17167576) +2 more
core +1 more source
Effectiveness and Safety Outcomes After Switching from Reference Biologics to Biosimilars for Treatment of Non-Infectious Uveitis: A Systematic Review and Meta-Analysis. [PDF]
Felfeli T +8 more
europepmc +1 more source
Biosimilar Development Considerations for Therapeutic Proteins With Limited Systemic Exposure: A Landscape Analysis and Pathway Evaluation. [PDF]
Wang T +5 more
europepmc +1 more source
Biosimilars in diabetic macular edema: Promise, progress, and pitfalls. [PDF]
Jain V +4 more
europepmc +1 more source
Clinical Outcomes Following Mandatory Switching to an Adalimumab Biosimilar in Patients with Psoriasis: A Real-world Single-centre Experience. [PDF]
D'Aquino MS, Amorim Filho RM, Amorim GM.
europepmc +1 more source
Real-World Analysis of Switching Between Ranibizumab Biosimilars: Safety and Results - a Multicenter Retrospective Observational Study. [PDF]
Chakraborty D +7 more
europepmc +1 more source

